354 related articles for article (PubMed ID: 10416607)
41. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
42. Heparanase, tissue factor, and cancer.
Nadir Y; Vlodavsky I; Brenner B
Semin Thromb Hemost; 2008 Mar; 34(2):187-94. PubMed ID: 18645924
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides.
Miao HQ; Elkin M; Aingorn E; Ishai-Michaeli R; Stein CA; Vlodavsky I
Int J Cancer; 1999 Oct; 83(3):424-31. PubMed ID: 10495437
[TBL] [Abstract][Full Text] [Related]
44. High-throughput methods for measuring heparanase activity and screening potential antimetastatic and anti-inflammatory agents.
Huang KS; Holmgren J; Reik L; Lucas-McGady D; Roberts J; Liu CM; Levin W
Anal Biochem; 2004 Oct; 333(2):389-98. PubMed ID: 15450817
[TBL] [Abstract][Full Text] [Related]
45. Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Maquoi E; Sounni NE; Devy L; Olivier F; Frankenne F; Krell HW; Grams F; Foidart JM; Noël A
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4038-47. PubMed ID: 15217936
[TBL] [Abstract][Full Text] [Related]
46. λ-Carrageenan Oligosaccharides of Distinct Anti-Heparanase and Anticoagulant Activities Inhibit MDA-MB-231 Breast Cancer Cell Migration.
Groult H; Cousin R; Chot-Plassot C; Maura M; Bridiau N; Piot JM; Maugard T; Fruitier-Arnaudin I
Mar Drugs; 2019 Feb; 17(3):. PubMed ID: 30818840
[TBL] [Abstract][Full Text] [Related]
47. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation.
Francis DJ; Parish CR; McGarry M; Santiago FS; Lowe HC; Brown KJ; Bingley JA; Hayward IP; Cowden WB; Campbell JH; Campbell GR; Chesterman CN; Khachigian LM
Circ Res; 2003 May; 92(8):e70-7. PubMed ID: 12690039
[TBL] [Abstract][Full Text] [Related]
48. Clinically relevant metastatic breast cancer models to study chemosensitivity.
Kim LS; Price JE
Methods Mol Med; 2005; 111():285-95. PubMed ID: 15911986
[TBL] [Abstract][Full Text] [Related]
49. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis.
Sato T; Yamaguchi A; Goi T; Hirono Y; Takeuchi K; Katayama K; Matsukawa S
J Surg Oncol; 2004 Sep; 87(4):174-81. PubMed ID: 15334632
[TBL] [Abstract][Full Text] [Related]
50. Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation.
Zetser A; Bashenko Y; Edovitsky E; Levy-Adam F; Vlodavsky I; Ilan N
Cancer Res; 2006 Feb; 66(3):1455-63. PubMed ID: 16452201
[TBL] [Abstract][Full Text] [Related]
51. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
52. Mechanism of anti-angiogenic activities of chitooligosaccharides may be through inhibiting heparanase activity.
Quan H; Zhu F; Han X; Xu Z; Zhao Y; Miao Z
Med Hypotheses; 2009 Aug; 73(2):205-6. PubMed ID: 19342181
[TBL] [Abstract][Full Text] [Related]
53. [Recent progress in the development of anti-tumor metastatic drugs].
Kumagai H
Gan To Kagaku Ryoho; 1995 Apr; 22(5):585-91. PubMed ID: 7536403
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
55. A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
Lyons JM; Anthony CT; Thomson JL; Woltering EA
Ann Surg Oncol; 2008 Dec; 15(12):3407-14. PubMed ID: 18795370
[TBL] [Abstract][Full Text] [Related]
56. Sulfated oligosaccharides and tumor: promoter or inhibitor?
Wu XZ
Panminerva Med; 2006 Mar; 48(1):27-31. PubMed ID: 16633329
[TBL] [Abstract][Full Text] [Related]
57. Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase.
Schoenfeld AK; Vierfuß S; Lühn S; Alban S
J Pharm Biomed Anal; 2014 Jul; 95():130-8. PubMed ID: 24667567
[TBL] [Abstract][Full Text] [Related]
58. [Carrageenan oligosaccharides inhibit growth-factor binding and heparanase activity].
Chen HM; Gao Y; Yan XJ
Yao Xue Xue Bao; 2011 Mar; 46(3):280-4. PubMed ID: 21626781
[TBL] [Abstract][Full Text] [Related]
59. The role of heparanase in diseases of the glomeruli.
Szymczak M; Kuźniar J; Klinger M
Arch Immunol Ther Exp (Warsz); 2010 Feb; 58(1):45-56. PubMed ID: 20049646
[TBL] [Abstract][Full Text] [Related]
60. Specific Inhibition of Heparanase by a Glycopolymer with Well-Defined Sulfation Pattern Prevents Breast Cancer Metastasis in Mice.
Loka RS; Sletten ET; Barash U; Vlodavsky I; Nguyen HM
ACS Appl Mater Interfaces; 2019 Jan; 11(1):244-254. PubMed ID: 30543095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
